These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 11327075)

  • 1. Tachyphylaxis in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
    Jones PH
    Am J Cardiol; 2001 Apr; 87(8):1032-4. PubMed ID: 11327075
    [No Abstract]   [Full Text] [Related]  

  • 2. Combinational effects of farnesoid X receptor antagonist and statin on plasma lipid levels and low-density lipoprotein clearance in guinea pigs.
    Amano Y; Ishikawa E; Shinozawa E; Shimada M; Miura S; Adachi R; Tozawa R
    Life Sci; 2014 Jul; 108(1):7-12. PubMed ID: 24805868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of atorvastatin on serum uric acid levels.
    Kakafika A; Tsimihodimos V; Elisaf M
    Atherosclerosis; 2001 Sep; 158(1):255. PubMed ID: 11550660
    [No Abstract]   [Full Text] [Related]  

  • 4. (TTA)n polymorphism in 3-hydroxy-3-methylglutaryl-coenzyme A and response to atorvastatin in coronary artery disease patients.
    Noriega V; Pennanen C; Sánchez MP; Chiong M; Llancaqueo M; Lavandero S; Prieto JC
    Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):211-5. PubMed ID: 19067673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HMG-CoA reductase inhibitors and renal function.
    Campese VM; Park J
    Clin J Am Soc Nephrol; 2007 Nov; 2(6):1100-3. PubMed ID: 17942762
    [No Abstract]   [Full Text] [Related]  

  • 6. Do the lipid responses to rosuvastatin and atorvastatin differ between Chinese and Caucasians? Comparison of the DISCOVERY-Hong Kong study with other DISCOVERY studies.
    Hu M; Lui SS; Ko GT; Tomlinson B
    Int J Cardiol; 2013 Oct; 168(3):3071-3. PubMed ID: 23642826
    [No Abstract]   [Full Text] [Related]  

  • 7. Beneficial effects of raloxifene and atorvastatin on serum lipids.
    Tsakok AD
    J Obstet Gynaecol; 2005 Feb; 25(2):228. PubMed ID: 15814427
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacodynamics and pharmacokinetic-pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor.
    Stern RH; Yang BB; Hounslow NJ; MacMahon M; Abel RB; Olson SC
    J Clin Pharmacol; 2000 Jun; 40(6):616-23. PubMed ID: 10868312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors.
    Cromwell WC; Ziajka PE
    Am J Cardiol; 2000 Nov; 86(10):1123-7. PubMed ID: 11074211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin.
    Bergstrom JD; Bostedor RG; Rew DJ; Geissler WM; Wright SD; Chao YS
    Biochim Biophys Acta; 1998 Jan; 1389(3):213-21. PubMed ID: 9512650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atorvastatin treatment prevents alterations in coronary smooth muscle nuclear Ca2+ signaling in diabetic dyslipidemia.
    Wamhoff BR; Dixon JL; Sturek M
    J Vasc Res; 2002; 39(3):208-20. PubMed ID: 12097819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atorvastatin: a new agent for hyperlipidemia.
    Kupecz D
    Nurse Pract; 1997 Nov; 22(11):87-8, 90, 93. PubMed ID: 9403876
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells.
    Mohammadi A; Macri J; Newton R; Romain T; Dulay D; Adeli K
    Arterioscler Thromb Vasc Biol; 1998 May; 18(5):783-93. PubMed ID: 9598838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atorvastatin treatment and vaccination efficacy.
    Packard RR; Schlegel S; Senouf D; Burger F; Sigaud P; Perneger T; Siegrist CA; Mach F
    J Clin Pharmacol; 2007 Aug; 47(8):1022-7. PubMed ID: 17548534
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of decreased plasma cholesterol by atorvastatin treatment on erythrocyte mechanical properties.
    Uyuklu M; Meiselman HJ; Baskurt OK
    Clin Hemorheol Microcirc; 2007; 36(1):25-33. PubMed ID: 17211059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tachyphylaxis and statin drugs.
    Stein JH; McBride PE
    Am J Cardiol; 2001 Mar; 87(5):674. PubMed ID: 11245286
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of ER-27856, a novel squalene synthase inhibitor, on plasma cholesterol in rhesus monkeys: comparison with 3-hydroxy-3-methylglutaryl-coa reductase inhibitors.
    Hiyoshi H; Yanagimachi M; Ito M; Ohtsuka I; Yoshida I; Saeki T; Tanaka H
    J Lipid Res; 2000 Jul; 41(7):1136-44. PubMed ID: 10884296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of atorvastatin on aldosterone production induced by glucose, LDL or angiotensin II in human renal mesangial cells.
    Nishikawa T; Matsuzawa Y; Suematsu S; Saito J; Omura M; Kino T
    Arzneimittelforschung; 2010; 60(7):445-51. PubMed ID: 20712135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet deposition on eroded vessel walls at a stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin.
    Alfon J; Royo T; Garcia-Moll X; Badimon L
    Arterioscler Thromb Vasc Biol; 1999 Jul; 19(7):1812-7. PubMed ID: 10397702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction.
    Silver MA; Langsjoen PH; Szabo S; Patil H; Zelinger A
    Am J Cardiol; 2004 Nov; 94(10):1306-10. PubMed ID: 15541254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.